| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Asthma | 5 | 2023 | 410 | 2.350 |
Why?
|
| Urinary Bladder Neoplasms | 9 | 2025 | 84 | 2.190 |
Why?
|
| Mesothelioma | 10 | 2025 | 148 | 1.380 |
Why?
|
| Neoplasms | 14 | 2022 | 1341 | 1.380 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2023 | 164 | 1.330 |
Why?
|
| Cannabis | 2 | 2023 | 90 | 1.270 |
Why?
|
| Smoking | 14 | 2021 | 1019 | 1.260 |
Why?
|
| Breast Neoplasms | 26 | 2025 | 1679 | 1.180 |
Why?
|
| Hematuria | 2 | 2025 | 6 | 1.180 |
Why?
|
| Quality of Life | 10 | 2020 | 599 | 1.160 |
Why?
|
| Early Detection of Cancer | 2 | 2024 | 428 | 1.130 |
Why?
|
| Survivors | 7 | 2021 | 152 | 1.070 |
Why?
|
| Humans | 114 | 2025 | 42163 | 1.000 |
Why?
|
| Female | 86 | 2025 | 24018 | 0.910 |
Why?
|
| Mammography | 14 | 2014 | 211 | 0.850 |
Why?
|
| Adolescent Behavior | 5 | 2021 | 270 | 0.840 |
Why?
|
| Hawaii | 33 | 2025 | 2004 | 0.830 |
Why?
|
| Colonoscopy | 1 | 2024 | 117 | 0.830 |
Why?
|
| Areca | 2 | 2020 | 33 | 0.790 |
Why?
|
| Middle Aged | 55 | 2025 | 11819 | 0.780 |
Why?
|
| Aged | 40 | 2025 | 7982 | 0.770 |
Why?
|
| HMGB1 Protein | 5 | 2023 | 30 | 0.750 |
Why?
|
| Respiratory Tract Diseases | 1 | 2022 | 30 | 0.750 |
Why?
|
| Male | 51 | 2025 | 22779 | 0.730 |
Why?
|
| Colorectal Neoplasms | 2 | 2024 | 502 | 0.710 |
Why?
|
| Marijuana Smoking | 1 | 2021 | 90 | 0.660 |
Why?
|
| Information Seeking Behavior | 1 | 2020 | 26 | 0.650 |
Why?
|
| Adult | 48 | 2025 | 13458 | 0.630 |
Why?
|
| Adolescent | 23 | 2024 | 5950 | 0.600 |
Why?
|
| Acculturation | 1 | 2020 | 203 | 0.580 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 3 | 2023 | 23 | 0.550 |
Why?
|
| Lung Neoplasms | 5 | 2025 | 479 | 0.550 |
Why?
|
| Exercise | 2 | 2019 | 674 | 0.520 |
Why?
|
| Asbestos | 3 | 2023 | 57 | 0.520 |
Why?
|
| Ubiquitin Thiolesterase | 4 | 2025 | 55 | 0.500 |
Why?
|
| Cross-Sectional Studies | 13 | 2024 | 3077 | 0.470 |
Why?
|
| Body Composition | 3 | 2021 | 160 | 0.470 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2020 | 959 | 0.420 |
Why?
|
| Breast | 6 | 2014 | 139 | 0.420 |
Why?
|
| Premenopause | 9 | 2013 | 109 | 0.420 |
Why?
|
| Risk Factors | 23 | 2023 | 3942 | 0.400 |
Why?
|
| Germ-Line Mutation | 2 | 2025 | 74 | 0.390 |
Why?
|
| Attitude to Health | 3 | 2020 | 336 | 0.370 |
Why?
|
| Nipple Aspirate Fluid | 4 | 2013 | 14 | 0.370 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2025 | 150 | 0.370 |
Why?
|
| Complementary Therapies | 2 | 2012 | 51 | 0.370 |
Why?
|
| Soy Foods | 4 | 2013 | 60 | 0.360 |
Why?
|
| Young Adult | 15 | 2022 | 4936 | 0.340 |
Why?
|
| Whole Body Imaging | 2 | 2021 | 25 | 0.340 |
Why?
|
| Prevalence | 11 | 2023 | 1597 | 0.330 |
Why?
|
| Prognosis | 11 | 2025 | 850 | 0.330 |
Why?
|
| Tumor Suppressor Proteins | 4 | 2025 | 222 | 0.320 |
Why?
|
| Aged, 80 and over | 14 | 2025 | 2803 | 0.320 |
Why?
|
| Sickness Impact Profile | 2 | 2007 | 25 | 0.310 |
Why?
|
| Psychometrics | 3 | 2020 | 350 | 0.280 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2007 | 14 | 0.280 |
Why?
|
| Anthropometry | 4 | 2021 | 96 | 0.270 |
Why?
|
| Telemedicine | 2 | 2021 | 215 | 0.270 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 2 | 2018 | 31 | 0.270 |
Why?
|
| Aid to Families with Dependent Children | 1 | 2007 | 1 | 0.270 |
Why?
|
| Morinda | 2 | 2021 | 9 | 0.260 |
Why?
|
| Colonic Neoplasms | 2 | 2020 | 223 | 0.250 |
Why?
|
| Health Behavior | 5 | 2020 | 568 | 0.250 |
Why?
|
| Psychiatric Status Rating Scales | 3 | 2017 | 280 | 0.240 |
Why?
|
| Neoplasm Staging | 10 | 2021 | 366 | 0.240 |
Why?
|
| Absorptiometry, Photon | 3 | 2021 | 74 | 0.240 |
Why?
|
| Breast Feeding | 1 | 2007 | 123 | 0.240 |
Why?
|
| Menthol | 2 | 2015 | 23 | 0.230 |
Why?
|
| Immunoassay | 1 | 2025 | 69 | 0.230 |
Why?
|
| Pilot Projects | 7 | 2024 | 733 | 0.220 |
Why?
|
| Isoflavones | 5 | 2012 | 132 | 0.220 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2021 | 933 | 0.220 |
Why?
|
| Prospective Studies | 6 | 2025 | 1574 | 0.220 |
Why?
|
| Students | 4 | 2017 | 617 | 0.210 |
Why?
|
| Cultural Diversity | 2 | 2002 | 187 | 0.210 |
Why?
|
| Plasminogen Activator Inhibitor 2 | 2 | 2022 | 3 | 0.210 |
Why?
|
| Reproducibility of Results | 6 | 2024 | 1058 | 0.210 |
Why?
|
| Caregivers | 3 | 2021 | 195 | 0.210 |
Why?
|
| User-Computer Interface | 1 | 2024 | 74 | 0.210 |
Why?
|
| United States | 7 | 2021 | 5072 | 0.200 |
Why?
|
| Adaptation, Psychological | 3 | 2017 | 410 | 0.200 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2015 | 246 | 0.200 |
Why?
|
| Receptors, Progesterone | 3 | 2025 | 90 | 0.190 |
Why?
|
| Quality of Health Care | 2 | 2021 | 158 | 0.190 |
Why?
|
| Prostatic Neoplasms | 2 | 2021 | 1068 | 0.190 |
Why?
|
| Veterans | 1 | 2024 | 203 | 0.190 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2020 | 727 | 0.190 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2023 | 85 | 0.190 |
Why?
|
| Age Factors | 7 | 2019 | 1139 | 0.190 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2019 | 89 | 0.190 |
Why?
|
| BCG Vaccine | 1 | 2022 | 12 | 0.190 |
Why?
|
| Receptors, Estrogen | 3 | 2025 | 177 | 0.180 |
Why?
|
| Adipose Tissue | 2 | 2021 | 180 | 0.180 |
Why?
|
| Carotenoids | 2 | 2014 | 74 | 0.180 |
Why?
|
| Gene Expression Profiling | 1 | 2025 | 683 | 0.180 |
Why?
|
| Smoking Cessation | 4 | 2024 | 583 | 0.180 |
Why?
|
| Rural Population | 1 | 2024 | 352 | 0.180 |
Why?
|
| California | 1 | 2023 | 531 | 0.180 |
Why?
|
| Asbestosis | 1 | 2020 | 7 | 0.170 |
Why?
|
| Receptor, erbB-2 | 2 | 2023 | 149 | 0.170 |
Why?
|
| Postmenopause | 5 | 2014 | 139 | 0.170 |
Why?
|
| Health Surveys | 2 | 2020 | 401 | 0.170 |
Why?
|
| Retrospective Studies | 7 | 2025 | 2485 | 0.170 |
Why?
|
| Uveal Neoplasms | 1 | 2020 | 11 | 0.170 |
Why?
|
| RecQ Helicases | 1 | 2020 | 35 | 0.170 |
Why?
|
| Receptors, Calcitriol | 1 | 2021 | 69 | 0.170 |
Why?
|
| Health Literacy | 1 | 2022 | 120 | 0.160 |
Why?
|
| Micronesia | 1 | 2020 | 87 | 0.160 |
Why?
|
| Estrogens | 2 | 2012 | 202 | 0.160 |
Why?
|
| Philippines | 5 | 2015 | 80 | 0.160 |
Why?
|
| Activities of Daily Living | 2 | 2013 | 136 | 0.160 |
Why?
|
| Knee | 1 | 2019 | 8 | 0.160 |
Why?
|
| Japan | 7 | 2012 | 348 | 0.160 |
Why?
|
| Dance Therapy | 1 | 2019 | 4 | 0.160 |
Why?
|
| Population Surveillance | 5 | 2012 | 245 | 0.160 |
Why?
|
| Health Status Indicators | 2 | 2013 | 90 | 0.160 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2023 | 860 | 0.160 |
Why?
|
| Parity | 2 | 2012 | 60 | 0.160 |
Why?
|
| Kidney Neoplasms | 1 | 2020 | 77 | 0.160 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 209 | 0.150 |
Why?
|
| Vitamin D | 2 | 2013 | 196 | 0.150 |
Why?
|
| Interleukin-15 | 1 | 2019 | 13 | 0.150 |
Why?
|
| Melanoma | 1 | 2020 | 109 | 0.150 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 2 | 2011 | 11 | 0.150 |
Why?
|
| Estrone | 2 | 2011 | 21 | 0.150 |
Why?
|
| Registries | 5 | 2017 | 431 | 0.150 |
Why?
|
| Heterozygote | 3 | 2025 | 107 | 0.150 |
Why?
|
| Respiration Disorders | 1 | 2018 | 9 | 0.150 |
Why?
|
| Fatigue | 2 | 2017 | 97 | 0.150 |
Why?
|
| Continuity of Patient Care | 1 | 2020 | 118 | 0.150 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2020 | 158 | 0.150 |
Why?
|
| Nicotine | 3 | 2018 | 290 | 0.140 |
Why?
|
| Flavoring Agents | 1 | 2018 | 22 | 0.140 |
Why?
|
| Skin Neoplasms | 1 | 2020 | 175 | 0.140 |
Why?
|
| Up-Regulation | 1 | 2021 | 534 | 0.140 |
Why?
|
| Cross-Cultural Comparison | 2 | 2013 | 109 | 0.140 |
Why?
|
| Aldehydes | 1 | 2018 | 69 | 0.140 |
Why?
|
| Liver Neoplasms | 1 | 2020 | 211 | 0.140 |
Why?
|
| Case-Control Studies | 8 | 2014 | 1266 | 0.140 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2024 | 547 | 0.140 |
Why?
|
| Pyruvates | 1 | 2017 | 6 | 0.130 |
Why?
|
| Risk-Taking | 1 | 2020 | 456 | 0.130 |
Why?
|
| Soybean Proteins | 3 | 2011 | 38 | 0.130 |
Why?
|
| Socioeconomic Factors | 4 | 2019 | 1221 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2016 | 11 | 0.130 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2016 | 15 | 0.130 |
Why?
|
| Ovarian Neoplasms | 1 | 2021 | 406 | 0.130 |
Why?
|
| Estradiol | 2 | 2011 | 269 | 0.130 |
Why?
|
| Chromosome Deletion | 1 | 2016 | 53 | 0.130 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2016 | 51 | 0.130 |
Why?
|
| Ribonuclease, Pancreatic | 1 | 2016 | 30 | 0.130 |
Why?
|
| Behavior, Addictive | 1 | 2016 | 37 | 0.120 |
Why?
|
| Proteins | 1 | 2019 | 383 | 0.120 |
Why?
|
| Diet | 5 | 2013 | 810 | 0.120 |
Why?
|
| Child | 5 | 2024 | 3381 | 0.120 |
Why?
|
| Mutation | 4 | 2023 | 1169 | 0.120 |
Why?
|
| Sensitivity and Specificity | 3 | 2025 | 602 | 0.120 |
Why?
|
| Pleural Neoplasms | 1 | 2016 | 57 | 0.120 |
Why?
|
| Radiation, Ionizing | 1 | 2015 | 13 | 0.120 |
Why?
|
| Time Factors | 6 | 2011 | 1848 | 0.110 |
Why?
|
| Radiation Injuries | 1 | 2015 | 23 | 0.110 |
Why?
|
| Perception | 3 | 2021 | 209 | 0.110 |
Why?
|
| Cross-Over Studies | 5 | 2013 | 112 | 0.110 |
Why?
|
| Infant | 4 | 2015 | 1143 | 0.110 |
Why?
|
| Animals | 9 | 2023 | 16695 | 0.110 |
Why?
|
| Ubiquinone | 1 | 2014 | 22 | 0.110 |
Why?
|
| Tocopherols | 1 | 2014 | 61 | 0.100 |
Why?
|
| Motivation | 1 | 2017 | 492 | 0.100 |
Why?
|
| Vitamin A | 1 | 2014 | 85 | 0.100 |
Why?
|
| Environmental Exposure | 1 | 2016 | 247 | 0.100 |
Why?
|
| Vitamins | 1 | 2014 | 81 | 0.100 |
Why?
|
| Mice | 6 | 2023 | 6490 | 0.100 |
Why?
|
| Neoplasm Invasiveness | 2 | 2021 | 284 | 0.100 |
Why?
|
| Fetal Blood | 1 | 2013 | 48 | 0.100 |
Why?
|
| Survival Rate | 4 | 2011 | 353 | 0.100 |
Why?
|
| Mammary Glands, Human | 1 | 2013 | 40 | 0.100 |
Why?
|
| Antibody Affinity | 1 | 2012 | 21 | 0.100 |
Why?
|
| Pregnancy Complications, Parasitic | 1 | 2012 | 10 | 0.100 |
Why?
|
| Physical Fitness | 1 | 2013 | 93 | 0.090 |
Why?
|
| Pregnancy | 4 | 2013 | 1737 | 0.090 |
Why?
|
| Antigens, Protozoan | 1 | 2012 | 74 | 0.090 |
Why?
|
| Reproductive History | 1 | 2012 | 27 | 0.090 |
Why?
|
| Cause of Death | 1 | 2012 | 183 | 0.090 |
Why?
|
| Urinalysis | 2 | 2022 | 34 | 0.090 |
Why?
|
| Nipples | 1 | 2011 | 18 | 0.090 |
Why?
|
| Tobacco Use Disorder | 1 | 2015 | 249 | 0.090 |
Why?
|
| Vitamin D Deficiency | 1 | 2013 | 107 | 0.090 |
Why?
|
| Cohort Studies | 5 | 2011 | 1729 | 0.090 |
Why?
|
| Malaria, Falciparum | 1 | 2012 | 91 | 0.090 |
Why?
|
| Stress, Psychological | 1 | 2017 | 641 | 0.090 |
Why?
|
| Logistic Models | 4 | 2019 | 1001 | 0.080 |
Why?
|
| Nutritional Physiological Phenomena | 2 | 2011 | 36 | 0.080 |
Why?
|
| Focus Groups | 2 | 2024 | 398 | 0.080 |
Why?
|
| Incidence | 5 | 2020 | 1054 | 0.080 |
Why?
|
| Emigrants and Immigrants | 1 | 2013 | 156 | 0.080 |
Why?
|
| Schools | 3 | 2017 | 283 | 0.080 |
Why?
|
| gamma-Tocopherol | 1 | 2010 | 19 | 0.080 |
Why?
|
| Cell Movement | 3 | 2021 | 640 | 0.080 |
Why?
|
| Epithelial Cells | 1 | 2013 | 426 | 0.080 |
Why?
|
| Adiposity | 1 | 2011 | 155 | 0.080 |
Why?
|
| Motor Activity | 1 | 2013 | 438 | 0.080 |
Why?
|
| Women's Health | 1 | 2011 | 158 | 0.080 |
Why?
|
| Micronutrients | 1 | 2010 | 45 | 0.080 |
Why?
|
| Follow-Up Studies | 4 | 2016 | 1051 | 0.080 |
Why?
|
| Obesity | 2 | 2010 | 1131 | 0.080 |
Why?
|
| Nonlinear Dynamics | 2 | 2013 | 35 | 0.080 |
Why?
|
| Scopoletin | 1 | 2009 | 3 | 0.080 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2009 | 14 | 0.080 |
Why?
|
| C-Reactive Protein | 1 | 2010 | 164 | 0.080 |
Why?
|
| Leptin | 1 | 2010 | 118 | 0.080 |
Why?
|
| Patient Compliance | 1 | 2010 | 225 | 0.070 |
Why?
|
| Regression Analysis | 4 | 2015 | 487 | 0.070 |
Why?
|
| Neovascularization, Pathologic | 2 | 2022 | 137 | 0.070 |
Why?
|
| Odds Ratio | 4 | 2015 | 587 | 0.070 |
Why?
|
| Predictive Value of Tests | 3 | 2006 | 438 | 0.070 |
Why?
|
| Survival Analysis | 3 | 2021 | 362 | 0.070 |
Why?
|
| Longitudinal Studies | 3 | 2022 | 1020 | 0.070 |
Why?
|
| Phytotherapy | 1 | 2009 | 78 | 0.070 |
Why?
|
| Cell Proliferation | 3 | 2021 | 1420 | 0.070 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2012 | 471 | 0.070 |
Why?
|
| Control Groups | 1 | 2007 | 2 | 0.070 |
Why?
|
| Phenotype | 2 | 2025 | 774 | 0.070 |
Why?
|
| Linear Models | 2 | 2021 | 311 | 0.070 |
Why?
|
| Child, Preschool | 3 | 2019 | 1516 | 0.070 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2007 | 27 | 0.070 |
Why?
|
| Prolactin | 1 | 2007 | 64 | 0.070 |
Why?
|
| Proportional Hazards Models | 4 | 2013 | 512 | 0.070 |
Why?
|
| Sex Factors | 2 | 2019 | 1008 | 0.070 |
Why?
|
| Aging | 1 | 2013 | 764 | 0.070 |
Why?
|
| Maternal-Child Health Centers | 1 | 2007 | 4 | 0.070 |
Why?
|
| Nursing Research | 1 | 2007 | 16 | 0.070 |
Why?
|
| Healthy People Programs | 1 | 2007 | 25 | 0.070 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2007 | 81 | 0.070 |
Why?
|
| Likelihood Functions | 1 | 2007 | 62 | 0.070 |
Why?
|
| Neoplasm Proteins | 1 | 2009 | 228 | 0.070 |
Why?
|
| Risk Assessment | 2 | 2025 | 845 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2016 | 456 | 0.060 |
Why?
|
| Cell Line, Tumor | 3 | 2021 | 2598 | 0.060 |
Why?
|
| Inflammation | 2 | 2023 | 729 | 0.060 |
Why?
|
| Models, Statistical | 1 | 2007 | 190 | 0.060 |
Why?
|
| Self Efficacy | 2 | 2019 | 211 | 0.060 |
Why?
|
| Feeding Behavior | 2 | 2007 | 461 | 0.060 |
Why?
|
| Interviews as Topic | 1 | 2007 | 428 | 0.060 |
Why?
|
| Mice, Knockout | 2 | 2020 | 1010 | 0.060 |
Why?
|
| Pedigree | 1 | 2025 | 94 | 0.060 |
Why?
|
| Internet | 2 | 2017 | 234 | 0.060 |
Why?
|
| Cotinine | 2 | 2015 | 44 | 0.060 |
Why?
|
| Risk | 2 | 2016 | 289 | 0.060 |
Why?
|
| Cultural Characteristics | 1 | 2005 | 128 | 0.060 |
Why?
|
| ROC Curve | 2 | 2021 | 157 | 0.060 |
Why?
|
| Progesterone | 1 | 2005 | 120 | 0.060 |
Why?
|
| Life Style | 1 | 2007 | 326 | 0.060 |
Why?
|
| Body Mass Index | 4 | 2011 | 916 | 0.060 |
Why?
|
| Alcohol Drinking | 2 | 2007 | 585 | 0.050 |
Why?
|
| Depression | 2 | 2017 | 837 | 0.050 |
Why?
|
| Guideline Adherence | 1 | 2005 | 98 | 0.050 |
Why?
|
| Demography | 1 | 2004 | 195 | 0.050 |
Why?
|
| Saliva | 2 | 2015 | 115 | 0.050 |
Why?
|
| Infant, Newborn | 1 | 2007 | 960 | 0.050 |
Why?
|
| Disease-Free Survival | 2 | 2016 | 116 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 2 | 2017 | 506 | 0.050 |
Why?
|
| Treatment Outcome | 2 | 2019 | 1586 | 0.050 |
Why?
|
| Overweight | 1 | 2006 | 248 | 0.050 |
Why?
|
| Chronic Disease | 1 | 2007 | 541 | 0.050 |
Why?
|
| Plant Extracts | 2 | 2021 | 303 | 0.050 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2023 | 25 | 0.050 |
Why?
|
| Models, Psychological | 1 | 2003 | 141 | 0.050 |
Why?
|
| Neoadjuvant Therapy | 1 | 2023 | 23 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 2 | 2019 | 1804 | 0.050 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 2022 | 7 | 0.050 |
Why?
|
| Disease Models, Animal | 2 | 2019 | 1554 | 0.050 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2022 | 25 | 0.050 |
Why?
|
| SEER Program | 1 | 2003 | 157 | 0.050 |
Why?
|
| Sick Role | 1 | 2002 | 9 | 0.050 |
Why?
|
| Administration, Intravesical | 1 | 2022 | 5 | 0.050 |
Why?
|
| Depressive Disorder | 1 | 2003 | 185 | 0.050 |
Why?
|
| Selection Bias | 1 | 2021 | 13 | 0.050 |
Why?
|
| Tissue Extracts | 1 | 2021 | 10 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2019 | 1112 | 0.040 |
Why?
|
| Heterogeneous-Nuclear Ribonucleoprotein Group A-B | 1 | 2021 | 11 | 0.040 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2021 | 32 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2023 | 379 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2021 | 153 | 0.040 |
Why?
|
| Asbestos, Crocidolite | 1 | 2020 | 8 | 0.040 |
Why?
|
| Language | 1 | 2022 | 181 | 0.040 |
Why?
|
| alpha-Fetoproteins | 1 | 2020 | 31 | 0.040 |
Why?
|
| Genomic Instability | 1 | 2020 | 36 | 0.040 |
Why?
|
| beta Catenin | 1 | 2021 | 75 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2021 | 238 | 0.040 |
Why?
|
| Genomics | 1 | 2022 | 289 | 0.040 |
Why?
|
| Prostate-Specific Antigen | 1 | 2021 | 145 | 0.040 |
Why?
|
| Nitrosamines | 1 | 2020 | 11 | 0.040 |
Why?
|
| Double-Blind Method | 2 | 2011 | 305 | 0.040 |
Why?
|
| Biopsy | 1 | 2020 | 176 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2022 | 249 | 0.040 |
Why?
|
| Neoplasm Metastasis | 1 | 2021 | 233 | 0.040 |
Why?
|
| Communication | 1 | 2022 | 207 | 0.040 |
Why?
|
| Lipoproteins, HDL | 1 | 2019 | 48 | 0.040 |
Why?
|
| Tobacco, Smokeless | 1 | 2019 | 19 | 0.040 |
Why?
|
| Family | 1 | 2020 | 192 | 0.040 |
Why?
|
| Triglycerides | 1 | 2019 | 146 | 0.040 |
Why?
|
| Guam | 1 | 2019 | 83 | 0.040 |
Why?
|
| Mycobacterium bovis | 1 | 2019 | 14 | 0.040 |
Why?
|
| Base Sequence | 1 | 2021 | 997 | 0.040 |
Why?
|
| China | 2 | 2012 | 233 | 0.040 |
Why?
|
| Fructose | 1 | 2018 | 23 | 0.040 |
Why?
|
| Sucrose | 1 | 2018 | 33 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2019 | 233 | 0.040 |
Why?
|
| Lymphocytes | 1 | 2019 | 124 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2019 | 293 | 0.030 |
Why?
|
| Insulin | 1 | 2019 | 255 | 0.030 |
Why?
|
| Azoxymethane | 1 | 2017 | 7 | 0.030 |
Why?
|
| Enterocytes | 1 | 2017 | 4 | 0.030 |
Why?
|
| Models, Biological | 1 | 2021 | 711 | 0.030 |
Why?
|
| Norway | 2 | 2007 | 10 | 0.030 |
Why?
|
| HT29 Cells | 1 | 2017 | 60 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2017 | 50 | 0.030 |
Why?
|
| Minority Groups | 1 | 2022 | 663 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 309 | 0.030 |
Why?
|
| Mental Health | 1 | 2021 | 363 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2017 | 158 | 0.030 |
Why?
|
| Arizona | 2 | 2007 | 118 | 0.030 |
Why?
|
| Cyclooxygenase 2 | 1 | 2017 | 106 | 0.030 |
Why?
|
| DNA Copy Number Variations | 1 | 2016 | 37 | 0.030 |
Why?
|
| Glucose | 1 | 2018 | 242 | 0.030 |
Why?
|
| Oncogene Proteins | 1 | 2016 | 22 | 0.030 |
Why?
|
| Multigene Family | 1 | 2016 | 105 | 0.030 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2016 | 61 | 0.030 |
Why?
|
| Pleural Effusion | 1 | 2016 | 8 | 0.030 |
Why?
|
| Genome, Human | 1 | 2016 | 143 | 0.030 |
Why?
|
| Gene Silencing | 1 | 2016 | 154 | 0.030 |
Why?
|
| Acetylation | 1 | 2016 | 108 | 0.030 |
Why?
|
| Osteopontin | 1 | 2016 | 45 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2017 | 339 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2018 | 658 | 0.030 |
Why?
|
| Alleles | 1 | 2016 | 352 | 0.030 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2016 | 78 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2017 | 686 | 0.030 |
Why?
|
| RNA Interference | 1 | 2016 | 246 | 0.030 |
Why?
|
| Carbon Monoxide | 1 | 2015 | 48 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2015 | 236 | 0.030 |
Why?
|
| Cytokines | 1 | 2019 | 661 | 0.030 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2015 | 40 | 0.030 |
Why?
|
| Health Status Disparities | 1 | 2021 | 705 | 0.030 |
Why?
|
| Los Angeles | 2 | 2006 | 390 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2016 | 452 | 0.030 |
Why?
|
| Social Behavior | 1 | 2015 | 160 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2016 | 436 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2015 | 279 | 0.030 |
Why?
|
| Promoter Regions, Genetic | 1 | 2016 | 534 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2016 | 274 | 0.030 |
Why?
|
| Histones | 1 | 2015 | 194 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 2 | 2005 | 225 | 0.020 |
Why?
|
| Lactation | 1 | 2013 | 44 | 0.020 |
Why?
|
| Sunlight | 1 | 2013 | 48 | 0.020 |
Why?
|
| DNA Methylation | 1 | 2016 | 393 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2012 | 162 | 0.020 |
Why?
|
| Seasons | 1 | 2013 | 133 | 0.020 |
Why?
|
| Hydroxyestrones | 1 | 2012 | 8 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2012 | 98 | 0.020 |
Why?
|
| Korea | 1 | 2012 | 37 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2016 | 1265 | 0.020 |
Why?
|
| Food Analysis | 1 | 2011 | 34 | 0.020 |
Why?
|
| Radioimmunoassay | 1 | 2011 | 70 | 0.020 |
Why?
|
| Cognition | 1 | 2015 | 458 | 0.020 |
Why?
|
| Flavonoids | 1 | 2012 | 94 | 0.020 |
Why?
|
| Dietary Supplements | 1 | 2013 | 208 | 0.020 |
Why?
|
| Specimen Handling | 1 | 2011 | 61 | 0.020 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2011 | 31 | 0.020 |
Why?
|
| Placebos | 1 | 2010 | 41 | 0.020 |
Why?
|
| Milk Proteins | 1 | 2010 | 29 | 0.020 |
Why?
|
| Anxiety | 1 | 2017 | 847 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2012 | 884 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2012 | 928 | 0.020 |
Why?
|
| Disease Progression | 1 | 2012 | 661 | 0.020 |
Why?
|
| Apoptosis | 1 | 2017 | 1541 | 0.020 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2011 | 230 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2017 | 2111 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2011 | 415 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2009 | 708 | 0.020 |
Why?
|
| Pain | 1 | 2009 | 283 | 0.010 |
Why?
|
| Nutrition Surveys | 1 | 2007 | 263 | 0.010 |
Why?
|
| Hormone Replacement Therapy | 1 | 2005 | 49 | 0.010 |
Why?
|
| Menopause | 1 | 2005 | 63 | 0.010 |
Why?
|
| Reference Values | 1 | 2005 | 207 | 0.010 |
Why?
|
| Mastectomy | 1 | 2005 | 16 | 0.010 |
Why?
|
| Radiotherapy | 1 | 2005 | 21 | 0.010 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2005 | 77 | 0.010 |
Why?
|
| Sex Distribution | 1 | 2005 | 224 | 0.010 |
Why?
|
| Insurance Claim Reporting | 1 | 2003 | 5 | 0.010 |
Why?
|
| Fourier Analysis | 1 | 2003 | 45 | 0.010 |
Why?
|
| Periodicity | 1 | 2003 | 34 | 0.010 |
Why?
|
| Body Weight | 1 | 2005 | 428 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2005 | 638 | 0.010 |
Why?
|
| Affect | 1 | 2003 | 177 | 0.010 |
Why?
|
| Comorbidity | 1 | 2003 | 725 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2005 | 979 | 0.010 |
Why?
|